Project Description



Multi-centre therapeutic trial targeting patients at risk, before the development of respiratory complications, including several treatment arms in an adaptive experimental plan, allowing the integration of drug candidates derived from research conducted in Lille and Lyon, as part of a reinforced long-standing partnership, as well as the physiopathological markers identified in the analysis of the Lille cohort.


The main objective is to confirm a pharmacological strategy in patients infected with covid-19, presenting co-morbidities likely to worsen their evolutionary prognosis, especially at the respiratory level.

The selection of pharmacological approaches is based on the repositioning of molecules with antiviral activity. The trial is ongoing and may include, if necessary, a therapeutic arm resulting from research advances in Lille.

Project initiator:

Karine FAURE